Etoposide increases equilibrative nucleoside transporter 1 activity and fluorothymidine uptake: Screening of 60 cytotoxic agents

Lee,Eun  Jung; Lee,Seung  Jin

doi:10.3892/or.2012.2172

Etoposide increases equilibrative nucleoside transporter 1 activity and fluorothymidine uptake: Screening of 60 cytotoxic agents

Authors:
- Eun Jung Lee
- Seung Jin Lee
View Affiliations

Affiliations: Institute for Innovative Cancer Research, Asan Institute for Life Sciences, Asan Medical Center, Seoul 138-736, Republic of Korea
Published online on: December 10, 2012 https://doi.org/10.3892/or.2012.2172
Pages: 763-770

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Equilibrative nucleoside transporter 1 (ENT1) is a major regulator for the uptake of [18F]fluorothymidine ([18F]FLT), a promising positron emission tomography tracer for treatment monitoring. Various antimetabolites such as 5-fluorouracil often increase ENT1 activity and [18F]FLT uptake (flare) in spite of cell death. However, it has not yet been defined which agents induce [18F]FLT flare and what is the role of [18F]FLT flare in cell viability. Sixty cytotoxic agents from the LOPAC1280 library were screened for ENT1 activity in HeLa cells which predominantly express ENT1, and topoisomerase inhibitors (i.e., aurintricarboxylic acid, idarubicin, camptothecin and etoposide) were identified as potent inducers of ENT1 activity. The changes in ENT1 activity were closely correlated with [3H]FLT uptake (Spearman's correlation coefficient, r=0.66; P<0.01). Etoposide significantly increased ENT1 activity and [3H]FLT uptake accompanying cell cycle arrest at S/G2/M phase and the increase in TK1 expression and activity in both ENT1-low expressing HT29 and ENT1-high expressing MDA-MB-231 cells. The inhibition of ENT1 activity by dipyridamol or S-(p-nitrobenzyl)-6-thioinosine repressed the etoposide-induced cell death in HeLa cells, whereas it induced no changes in the other cell lines. In conclusion, etoposide is identified as a potent inducer for ENT1 activity and [3H]FLT uptake. The role of ENT1 activity by etoposide was cell-type dependent, which requests caution for the application of ENT1-mediated [18F]FLT flare for treatment monitoring.

View Figures

View References

1	Shields AF, Grierson JR, Dohmen BM, et al: Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 4:1334–1336. 1998.
2	Dittmann H, Dohmen BM, Kehlbach R, et al: Early changes in [18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging. 29:1462–1469. 2002.
3	Kenny LM, Contractor KB, Stebbing J, et al: Altered tissue 3′-deoxy-3′-[18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography. Clin Cancer Res. 15:6649–6657. 2009.
4	Pillai RG, Forster M, Perumal M, et al: Imaging pharmacodynamics of the alpha-folate receptor-targeted thymidylate synthase inhibitor BGC 945. Cancer Res. 68:3827–3834. 2008. View Article : Google Scholar : PubMed/NCBI
5	Pressacco J, Wiley JS, Jamieson GP, Erlichman C and Hedley DW: Modulation of the equilibrative nucleoside transporter by inhibitors of DNA synthesis. Br J Cancer. 72:939–942. 1995. View Article : Google Scholar : PubMed/NCBI
6	Pressacco J, Mitrovski B, Erlichman C and Hedley DW: Effects of thymidylate synthase inhibition on thymidine kinase activity and nucleoside transporter expression. Cancer Res. 55:1505–1508. 1995.PubMed/NCBI
7	Lee SJ, Kim SY, Chung JH, Oh SJ, et al: Induction of thymidine kinase 1 after 5-fluorouracil as a mechanism for 3′-deoxy-3′-[18F]fluorothymidine flare. Biochem Pharmacol. 80:1528–1536. 2010.PubMed/NCBI
8	Perumal M, Pillai RG, Barthel H, et al: Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography. Cancer Res. 66:8558–8564. 2006. View Article : Google Scholar
9	Cruet-Hennequart S, Villalan S, Kaczmarczyk A, O’Meara E, Sokol AM and Carty MP: Characterization of the effects of cisplatin and carboplatin on cell cycle progression and DNA damage response activation in DNA polymerase eta-deficient human cells. Cell Cycle. 8:3039–3050. 2009. View Article : Google Scholar : PubMed/NCBI
10	Yau K, Price P, Pillai RG and Aboagye E: Elevation of radiolabelled thymidine uptake in RIF-1 fibrosarcoma and HT29 colon adenocarcinoma cells after treatment with thymidylate synthase inhibitors. Eur J Nucl Med Mol Imaging. 33:981–987. 2006. View Article : Google Scholar
11	Paproski RJ, Ng AM, Yao SY, Graham K, Young JD and Cass CE: The role of human nucleoside transporters in uptake of 3′-deoxy-3′-fluorothymidine. Mol Pharmacol. 74:1372–1380. 2008.
12	King AE, Ackley M, Cass CE, Young JD and Baldwin SA: Nucleoside transporters: from scavengers to novel therapeutic targets. Trends Pharmacol Sci. 27:416–425. 2006. View Article : Google Scholar : PubMed/NCBI
13	Cass CE, Dahlig E, Lau EY, Lynch TP and Paterson AR: Fluctuations in nucleoside uptake and binding of the inhibitor of nucleoside transport, nitrobenzylthioinosine, during the replication cycle of HeLa cells. Cancer Res. 39:1245–1252. 1979.PubMed/NCBI
14	Coe I, Zhang Y, McKenzie T and Naydenova Z: PKC regulation of the human equilibrative nucleoside transporter, hENT1. FEBS Lett. 517:201–205. 2002. View Article : Google Scholar : PubMed/NCBI
15	Huang M, Wang Y, Collins M, Gu JJ, Mitchell BS and Graves LM: Inhibition of nucleoside transport by p38 MAPK inhibitors. J Biol Chem. 277:28364–28367. 2002. View Article : Google Scholar : PubMed/NCBI
16	Huang M, Wang Y, Cogut SB, Mitchell BS and Graves LM: Inhibition of nucleoside transport by protein kinase inhibitors. J Pharmacol Exp Ther. 304:753–760. 2003. View Article : Google Scholar : PubMed/NCBI
17	Grem JL, Danenberg KD, Behan K, et al: Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute’s Anticancer Drug Screen. Clin Cancer Res. 7:999–1009. 2001.PubMed/NCBI
18	Lu X, Gong S, Monks A, Zaharevitz D and Moscow JA: Correlation of nucleoside and nucleobase transporter gene expression with antimetabolite drug cytotoxicity. J Exp Ther Oncol. 2:200–212. 2002. View Article : Google Scholar : PubMed/NCBI
19	Zhang JH, Chung TD and Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen. 4:67–73. 1999. View Article : Google Scholar : PubMed/NCBI
20	Plotnik DA, McLaughlin LJ, Krohn KA and Schwartz JL: The effects of 5-fluoruracil treatment on 3′-fluoro-3′-deoxythymidine (FLT) transport and metabolism in proliferating and non-proliferating cultures of human tumor cells. Nucl Med Biol. May 4–2012.(Epub ahead of print).
21	Liu L, Choi JH, Yim H, Choi JS, Park BD, Cho SJ and Lee SK: ATR (AT mutated Rad3 related) activity stabilizes Cdc6 and delays G2/M-phase entry during hydroxyurea-induced S-phase arrest of HeLa cells. Int J Biochem Cell Biol. 41:1410–1420. 2009. View Article : Google Scholar : PubMed/NCBI
22	Liu S, Xie Y, Lv Y, et al: A novel target of mizoribine inhibiting mesangial cell proliferation: S phase kinase-associated protein 2. Am J Nephrol. 32:447–455. 2010. View Article : Google Scholar : PubMed/NCBI